Clinical and Genetic Characteristics Associated With Survival Outcome in Late-Onset Huntington’s Disease in South Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose The onset of Huntington’s disease (HD) usually occurs before the age of 50 years, and the median survival time from onset is 15 years. We investigated survival in patients with late-onset HD (LoHD) (age at onset ≥60 years) and the associations of the number of mutant CAG repeats and age at onset (AAO) with survival in patients with HD. Methods Patients with genetically confirmed HD at six referral centers in South Korea between 2000 and 2020 were analyzed retrospectively. Baseline demographic, clinical, and genetic characteristics and the survival status as at December 2020 were collected. Results Eighty-seven patients were included, comprising 26 with LoHD (AAO=68.77±5.91 years, mean±standard deviation; 40.54±1.53 mutant CAG repeats) and 61 with common-onset HD (CoHD) (AAO=44.12±8.61 years, 44.72±4.27 mutant CAG repeats). The ages at death were 77.78±7.46 and 53.72±10.86 years in patients with LoHD and CoHD, respectively (p< 0.001). The estimated survival time was 15.21±2.49 years for all HD patients, and 10.74±1.95 and 16.15±2.82 years in patients with LoHD and CoHD, respectively. More mutant CAG repeats and higher AAO were associated with shorter survival (hazard ratio [HR]=1.05, 95% confidence interval [CI]=1.01–1.09, p=0.019; and HR=1.17, 95% CI=1.03–1.31, p=0.013; respectively) for all HD patients. The LoHD group showed no significant factors associated with survival after disease onset, whereas the number of mutant CAG repeats had a significant effect (HR=1.12, 95% CI=1.01–1.23, p=0.034) in the CoHD group. Conclusions Survival after disease onset was shorter in patients with LoHD than in those with CoHD. More mutant CAG repeats and higher AAO were associated with shorter survival in patients with HD.
Abstract
Background and Purpose The onset of Huntington’s disease (HD) usually occurs before the age of 50 years, and the median survival time from onset is 15 years. We investigated survival in patients with late-onset HD (LoHD) (age at onset ≥60 years) and the associations of the number of mutant CAG repeats and age at onset (AAO) with survival in patients with HD. Methods Patients with genetically confirmed HD at six referral centers in South Korea between 2000 and 2020 were analyzed retrospectively. Baseline demographic, clinical, and genetic characteristics and the survival status as at December 2020 were collected. Results Eighty-seven patients were included, comprising 26 with LoHD (AAO=68.77±5.91 years, mean±standard deviation; 40.54±1.53 mutant CAG repeats) and 61 with common-onset HD (CoHD) (AAO=44.12±8.61 years, 44.72±4.27 mutant CAG repeats). The ages at death were 77.78±7.46 and 53.72±10.86 years in patients with LoHD and CoHD, respectively (p< 0.001). The estimated survival time was 15.21±2.49 years for all HD patients, and 10.74±1.95 and 16.15±2.82 years in patients with LoHD and CoHD, respectively. More mutant CAG repeats and higher AAO were associated with shorter survival (hazard ratio [HR]=1.05, 95% confidence interval [CI]=1.01–1.09, p=0.019; and HR=1.17, 95% CI=1.03–1.31, p=0.013; respectively) for all HD patients. The LoHD group showed no significant factors associated with survival after disease onset, whereas the number of mutant CAG repeats had a significant effect (HR=1.12, 95% CI=1.01–1.23, p=0.034) in the CoHD group. Conclusions Survival after disease onset was shorter in patients with LoHD than in those with CoHD. More mutant CAG repeats and higher AAO were associated with shorter survival in patients with HD.
참고문헌 (26)
- Langbehn DR, "Longer CAG repeat length is associated with shorter survival after disease onset in Huntington disease", Am J Hum Genet, 109, pp.172~179 (2022)
- Volpi E, "Late-onset Huntington disease : an Italian cohort", J Clin Neurosci, 86, pp.58~63 (2021)
- Capiluppi E, "Late-onset Huntington’s disease with 40-42 CAG expansion", Neurol Sci, 41, pp.869~876 (2020)
- Kim HS, "Current status of Huntington’s disease in Korea : a nationwide survey and national registry analysis", J Mov Disord, 8, pp.14~20 (2015)
- Ross CA, "Huntington’s disease : from molecular pathogenesis to clinical treatment", Lancet Neurol, 10, pp.83~98 (2011)
- Chaganti SS, "What do we know about late onset Huntington’s disease?", J Huntingtons Dis, 6, pp.95~103 (2017)
- Xu M, "Huntington disease in Asia", Chin Med J(Engl), 128, pp.1815~1819 (2015)
- Oosterloo M, "Clinical and genetic characteristics of late-onset Huntington’s disease", Parkinsonism Relat Disord, 61, pp.101~105 (2019)
- Lipe H, "Late onset Huntington disease : clinical and genetic characteristics of 34 cases", J Neurol Sci, 276, pp.159~162 (2009)
- Kim HJ, "Survival of Korean Huntington’s disease patients", J Mov Disord, 9, pp.166~170 (2016)
- Chen SJ, "Clinical, radiological, and genetic characteristics in patients with Huntington’s disease in a Taiwanese cohort", Am J Med Genet B Neuropsychiatr Genet, 183, pp.352~359 (2020)
- Rosenblatt A, "Age, CAG repeat length, and clinical progression in Huntington’s disease", Mov Disord, 27, pp.272~276 (2012)
- Langbehn DR, "Association of CAG repeats with long-term progression in Huntington disease", JAMA Neurol, 76, pp.1375~1385 (2019)
- Rinaldi C, "Predictors of survival in a Huntington’s disease population from southern Italy", Can J Neurol Sci, 39, pp.48~51 (2012)
- Sipila JOT, "Comparison of midage-onset and late-onset Huntington’s disease in Finnish patients", J Neurol, 264, pp.2095~2100 (2017)
- Chao MJ, "Haplotype-based stratification of Huntington’s disease", Eur J Hum Genet, 25, pp.1202~1209 (2017)
- Keum JW, "The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease", Am J Hum Genet, 98, pp.287~298 (2016)
- Reilmann R, "Diagnostic criteria for Huntington’s disease based on natural history", Mov Disord, 29, pp.1335~1341 (2014)
- Karadag YS, "Huntington’s disease in Turkey : genetic counseling, clinical features, and outcome", Neurol Res, 43, pp.381~386 (2021)
- McCusker EA, "Prevalent nonmotor symptoms associated with Huntington disease : challenging to interpret and with early impact on function", Neurology, 96, pp.875~876 (2021)
- Hayward P, "Genes, environment, and the onset of Huntington’s disease", Lancet Neurol, 3, pp.199~ (2004)
- Anil M, "The clinical features and progression of late-onset versus younger-onset in an adult cohort of Huntington’s disease patients", J Huntingtons Dis, 9, pp.275~282 (2020)
- Kringlen G, "The impact of family history on the clinical features of Huntington’s disease", J Huntingtons Dis, 6, pp.327~335 (2017)
- Shin CW, "Preliminary analysis of Huntington’s disease in South Korea", J Huntingtons Dis, 2, pp.83~87 (2013)
- Singh A, "What has contributed to the large sex differentials in lifespan variation and life expectancy in South Korea?", J Biosoc Sci, 53, pp.396~406 (2021)
- Yang S, "Understanding the rapid increase in life expectancy in South Korea", Am J Public Health, 100, pp.896~903 (2010)